Geopolitics Alpha

Summit shares drop after US FDA declines to approve lung cancer drug

Published . Updated .

Covered by 2 outlets: Reuters, Yahoo Finance.

Who covered it: Center 2. How we rate outlets

Key takeaways

  • Nov 16 () - Shares of Summit Therapeutics fell nearly 20% in premarket trading on Monday after the US Food and Drug Administration ‌declined to approve its experimental lung cancer drug ivonescimab.
  • Exposed: XLV, XBI, LLY, JNJ, PFE
  • Market reaction: price tracking starts with the next trading session.

Market Call

Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.

Get these market calls by email

The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.

Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.

Summit shares drop after US FDA declines to approve lung cancer drug

Nov 16 () - Shares of Summit Therapeutics fell nearly 20% in premarket trading on Monday after the US Food and Drug Administration ‌declined to approve its experimental lung cancer drug ivonescimab. The regulator on ‌Sunday cited the drug's failure to achieve statistical

Directly affected

  • SMMT Summit Therapeutics

    Named in this report.

Indirectly affected

  • XLV Health Care Select Sector SPDR

    Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “drug” (pharma and health) in this story.

  • XBI SPDR S&P Biotech ETF

    SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “drug” (pharma and health) in this story.

  • LLY Eli Lilly and

    Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story.

  • JNJ Johnson & Johnson

    Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story.

  • PFE Pfizer

    Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story.

  • MRK Merck

    Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story.

Price reaction, T-5 to T+3

TickerT-5T-3T-1T0T+1T+2T+3
SMMTPrices arriving within minutes———after closeafter closeafter closeafter close
XLV-0.28%+0.04%baseafter closeafter closeafter closeafter close
XBI+4.20%+3.78%baseafter closeafter closeafter closeafter close
LLY-2.25%-0.49%baseafter closeafter closeafter closeafter close
JNJ-1.35%-1.97%baseafter closeafter closeafter closeafter close
PFE+1.19%+1.90%baseafter closeafter closeafter closeafter close
MRK+0.65%-0.38%baseafter closeafter closeafter closeafter close

Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.

Summit shares drop after US FDA declines to approve lung cancer drug Reuters

Source: Reuters

Price since this story was published: Select Sector Spdr Tr (XLV)

CompanyWhenMoveStatus
Johnson & Johnson (JNJ)three days earlier-1.97%final price
Johnson & Johnson (JNJ)five days earlier-1.35%final price
Eli Lilly (LLY)three days earlier-0.49%final price
Eli Lilly (LLY)five days earlier-2.25%final price
Merck (MRK)three days earlier-0.38%final price
Merck (MRK)five days earlier+0.65%final price
Pfizer (PFE)three days earlier+1.90%final price
Pfizer (PFE)five days earlier+1.19%final price
Spdr Series Trust (XBI)three days earlier+3.78%final price
Spdr Series Trust (XBI)five days earlier+4.20%final price
Select Sector Spdr Tr (XLV)three days earlier+0.04%final price
Select Sector Spdr Tr (XLV)five days earlier-0.28%final price

Trades by members of Congress and officials in the stocks in this story

Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).

Who gains and who loses around Select Sector Spdr Tr (XLV)

Companies tied to this story

  • XLV Select Sector Spdr Tr

    In “Summit shares drop after US FDA declines to approve lung cancer drug,” Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence. Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “drug” (pharma and health) in this story

  • XBI Spdr Series Trust

    For “Summit shares drop after US FDA declines to approve lung cancer drug,” Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence. Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “drug” (pharma and health) in this story

  • LLY Eli Lilly

    Eli Lilly (LLY) is linked, with no stored direction, medium confidence in the 16 Nov 2026 story “Summit shares drop after US FDA declines to approve lung cancer drug.” Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story

  • JNJ Johnson & Johnson

    In “Summit shares drop after US FDA declines to approve lung cancer drug,” Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence. Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story

  • PFE Pfizer

    Pfizer (PFE) is linked, with no stored direction, medium confidence in the 16 Nov 2026 story “Summit shares drop after US FDA declines to approve lung cancer drug.” Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story

  • MRK Merck

    For “Summit shares drop after US FDA declines to approve lung cancer drug,” Merck (MRK) is linked, with no stored direction, medium confidence. Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story

Select Sector Spdr Tr (XLV)

“Summit shares drop after US FDA declines to approve lung cancer drug” (16 Nov 2026) reaches Select Sector Spdr Tr (XLV) through this story.

For Select Sector Spdr Tr (XLV), the reason on file says Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “drug” (pharma and health) in this story

Also listed, Spdr Series Trust (XBI): SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “drug” (pharma and health) in this story

The price range for Select Sector Spdr Tr (XLV), and the dates in the story

LLY traded between 1239.21 and 1458.90 across 20 sessions. The latest close on file is 1430.09.

How strong the case is around Select Sector Spdr Tr (XLV)

54 out of 100

“Summit shares drop after US FDA declines to approve lung cancer drug” scores 54 out of 100. The score uses 2 sources, and 6 linked companies.